The partnership is set to capitalise on Viatris’ extensive global reach and expertise in the cardiovascular sector. Credit: Jo Panuwat D/Shutterstock.

Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise sotagliflozin in all indications outside the US and Europe.

The strategic partnership is set to capitalise on Viatris’ extensive global reach and expertise in the cardiovascular sector.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Viatris will make an upfront payment of $25m to Lexicon.

The deal also includes potential regulatory and sales milestone payments to Lexicon, along with tiered royalties on annual net sales ranging from low-double-digit to upper-teens.

Lexicon will retain commercialisation rights within the US and European markets while Viatris will utilise its Global Healthcare Gateway to facilitate access to sotagliflozin in other markets, ensuring a broader patient reach.

Lexicon CEO and director Dr Mike Exton stated: “We are pleased to be working with Viatris, a company with strong cardiometabolic expertise, global commercial capabilities and a successful track record of launching medicines in new territories. We are confident that this agreement will expand the reach of sotagliflozin to more patients in need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We plan to continue to evaluate strategic partnerships for additional assets, territories and indications to augment Lexicon’s development and commercial capabilities, advance our pipeline and expand access to our medicines to more patients around the world.” 

Sotagliflozin, known by the brand name INPEFA, is a dual inhibitor of sodium-glucose cotransporter types 2 and 1.

Lexicon will supply the medication to Viatris for both clinical and commercial purposes at an agreed transfer price.

The medicine received approval from the US Food and Drug Administration in May 2023. It is indicated for reducing the risk of cardiovascular death and hospitalisation due to heart failure and other cardiovascular-associated diseases.